Figure S7 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers

2026 Open access

Read full text
Authors: Michael Hulse, Min Wang, Chaoyi Xu, Jack Carter, Anjana Agarwal, Liang Lu, Philip Pitis, Neha Bhagwat, Joseph D. Rager, Justin Kurian, Corey Basch, Monisha Sivakumar
+36 more Jessica Burtell, Arpita Mondal, Alexander Grego, Andrew W. Moore, Carly Bachner, Komali Vykuntam, Anthony Reichelderfer, JiMin Park, Joy M. Cote, Miles Cowart, Olusola Peace Osinubi, Ludovic Bigot, Alice Da Silva, Catline Nobre, Melissandre Meteau, Miguel Soares, Hsin‐Yao Tang, Klare Bersch, Chaofeng Dai, Ganfeng Cao, Bo Shen, Tom Emm, Stefan U. Ruepp, Jennifer Xavier, Chris Tankersley, Diane Heiser, Sang Hyun Lee, Sandy Geeganage, Bruce Ruggeri, Hong Lin, William F. Novotny, Jane Huang, Kris Vaddi, Andrew P. Combs, Peggy Scherle, Koichi Ito
DOI: 10.1158/0008-5472.30986022
Cited by: 0

Abstract

PRT3789 single dose decreases SMARCA2 protein and KRT80 mRNA expression in NCI-H838 CDX model in mice

Fields of Study & Subjects

Chromatin Remodeling and Cancer Mechanisms of cancer metastasis RNA regulation and disease

Publication details

Publication date
2 January 2026